A new report from BioCrossroads shows dramatic gains in venture capital funding in Indiana’s life sciences sector. In 2022, 39 companies raised a total of $619 million. This is a 136% increase over 2020’s $262 million and a 65% increase over 2021’s $433 million. Since a comparable number of companies raised capital in those years,…
Indiana continues to lead in life sciences – now the top domestic exporter of drugs
BioCrossroads, which works to advance Indiana’s signature strengths in the life sciences industry, released new statistics on the industry showing that Indiana was the top exporter of pharmaceuticals across the United States in 2022. BioCrossroads also shared that Indiana’s life sciences sector now boasts 2,700 companies with 63,000 employees generating over $77 billion in economic output.…
Indiana bill would prevent physician non-competes
INDIANAPOLIS – Feb. 3, 2023 — Following a similar move also under consideration at the Federal Trade Commission, the Indiana legislature is considering a bill that would bar non-compete agreements for physicians…read more
Indianapolis-based Elevance Health reports FY2022 results – gaining 2.2 million members
INDIANAPOLIS – Feb. 3, 2023 — Similar growth in 2023 would mean Elevance could serve as many as 50 million people in the U.S. across Medicare, Medicaid and Commercial health plans…read more
Adrienne D. Sims, Psy.D., joins Indiana University Health as Sr. VP and chief human resources officer
INDIANAPOLIS – Adrienne D. Sims, Psy.D., has joined Indiana University Health as senior vice president and chief human resources officer. She was vice president of human resources & talent management for the past four years for OneAmerica Financial Partners, located in Indianapolis. Previously Sims was vice president of talent management at Dick’s Sporting Goods and served…
MBX Biosciences closes on $115M in drug-development funding
INDIANAPOLIS – Less than one month after initiating a multiple ascending dose study for its lead clinical asset, MBX Biosciences secured $115 million in Series B financing to advance its pipeline of Precision Endocrine Peptides for endocrine disorders. The funds, coupled with earlier Series A financing, provide the Indiana-based company with about $150 million in total funding that…